PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1391972
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1391972
Global bioengineered artificial skin market is value at US$ 3.32 Billion In 2023 and is expected to grow at a compound annual growth rate (CAGR) of 16.9% to reach US$ 9.92 Billion by 2030.
Report Coverage | Report Details | ||
---|---|---|---|
Base Year: | 2022 | Market Size in 2023: | US$ 3.32 Bn |
Historical Data for: | 2018 to 2021 | Forecast Period: | 2023 - 2030 |
Forecast Period 2023 to 2030 CAGR: | 16.90% | 2030 Value Projection: | US$ 9.92 Bn |
Bioengineered skin is designed to undertake the functions of the epidermis and/or dermis as a temporary usage till the patient's skin barrier spontaneously repairs itself naturally. Bioengineered skin is used to address severe scars which represents the result of the closure process of extended and deep skin wounds. Bioengineered skin autografts are derived from the patient's own skin cells that are grown or cultured in small amounts of skin or hair follicles. Bioengineered artificial skin is designed for the reconstruction of skin appendages, pigmentation, and nerves. Artificial skin can replace or can be used to replace the outer layer of the skin or the thick layer just underneath it (epidermis and dermis). The most used commercially available acellular dermal substitutes are composed of natural extracellular matrix components and can be divided in two categories: decellularized extracellular matrices and reconstructed extracellular matrices.
Rising number of road accidents, burns, and trauma-related incidents, high incidence of acute and chronic wounds (owing to the rise in burden of chronic diseases and growing geriatric population), increasing awareness among people about various skin treatments, and rise in demand for artificial skin are major factors expected to drive growth of the global bioengineered artificial skin market.
For instance, in June 2021, the U.S. Food and Drug Administration (FDA) approved StrataGraft for the treatment of adult patients with thermal burns, which contained intact dermal elements (remaining deep skin layers) for which surgical intervention is clinically indicated (also referred to as deep partial thickness burns). StrataGraft is produced from two kinds of human skin cells (keratinocytes and dermal fibroblasts) grown together to make a bi-layered construct (a cellularized scaffold).